Biotech company Oxford Biomedica increased its revenue in the first half of 2020 by 6%, it announced this morning. Bioprocessing and commercial development were particularly strong, posting revenues of £23.4m, up by 24%. The company recorded an operating loss of £5.8m for the first six months of the year, down from £6.1m in the first half of 2019. After a fundraising round, the group now has more than £50m in cash on its balance sheet. CEO John Dawson highlighted Oxford Biometrica's work with AstraZeneca, with which it has signed a three-year deal for large-scale manufacturing of a potential vaccine for COVID-19.
Sign up to our
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
UK 350 Risers and Fallers
Tweets not available.